JP2014531455A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014531455A5 JP2014531455A5 JP2014532040A JP2014532040A JP2014531455A5 JP 2014531455 A5 JP2014531455 A5 JP 2014531455A5 JP 2014532040 A JP2014532040 A JP 2014532040A JP 2014532040 A JP2014532040 A JP 2014532040A JP 2014531455 A5 JP2014531455 A5 JP 2014531455A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutical composition
- memory
- peptide
- amyloid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 80
- 230000000890 antigenic effect Effects 0.000 claims description 65
- 201000010374 Down Syndrome Diseases 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 33
- 206010027175 memory impairment Diseases 0.000 claims description 29
- 206010044688 Trisomy 21 Diseases 0.000 claims description 26
- 230000015654 memory Effects 0.000 claims description 21
- 230000005856 abnormality Effects 0.000 claims description 16
- 208000028698 Cognitive impairment Diseases 0.000 claims description 15
- 210000004556 brain Anatomy 0.000 claims description 15
- 208000010877 cognitive disease Diseases 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 102000007079 Peptide Fragments Human genes 0.000 claims description 13
- 108010033276 Peptide Fragments Proteins 0.000 claims description 13
- 230000002996 emotional effect Effects 0.000 claims description 11
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims description 9
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 230000001149 cognitive effect Effects 0.000 claims description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 8
- 239000002502 liposome Substances 0.000 claims description 7
- 235000021314 Palmitic acid Nutrition 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 230000035045 associative learning Effects 0.000 claims description 6
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 210000001320 hippocampus Anatomy 0.000 claims description 6
- 210000002442 prefrontal cortex Anatomy 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 210000002475 olfactory pathway Anatomy 0.000 claims description 5
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 4
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 4
- 206010003062 Apraxia Diseases 0.000 claims description 4
- 206010010904 Convulsion Diseases 0.000 claims description 4
- 208000002033 Myoclonus Diseases 0.000 claims description 4
- 206010034719 Personality change Diseases 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 238000013019 agitation Methods 0.000 claims description 4
- 201000007201 aphasia Diseases 0.000 claims description 4
- 230000036461 convulsion Effects 0.000 claims description 4
- 230000001073 episodic memory Effects 0.000 claims description 4
- 230000006870 function Effects 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 230000001771 impaired effect Effects 0.000 claims description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 4
- 230000000926 neurological effect Effects 0.000 claims description 4
- 208000020016 psychiatric disease Diseases 0.000 claims description 4
- 230000000007 visual effect Effects 0.000 claims description 4
- 239000000232 Lipid Bilayer Substances 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 108091000054 Prion Proteins 0.000 claims description 2
- 102000029797 Prion Human genes 0.000 claims description 2
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 2
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 102000013498 tau Proteins Human genes 0.000 claims description 2
- 108010026424 tau Proteins Proteins 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 230000006735 deficit Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000019771 cognition Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000001353 entorhinal cortex Anatomy 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 description 10
- 230000002708 enhancing effect Effects 0.000 description 6
- 230000004064 dysfunction Effects 0.000 description 3
- 201000003723 learning disability Diseases 0.000 description 3
- 230000003930 cognitive ability Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 150000002943 palmitic acids Chemical class 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- -1 huntingtin Proteins 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 201000011475 meningoencephalitis Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| USPCT/US2011/052992 | 2011-09-23 | ||
| USPCT/US2011/052992 | 2011-09-23 | ||
| PCT/US2012/056728 WO2013044147A1 (en) | 2011-09-23 | 2012-09-21 | Vaccine therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014531455A JP2014531455A (ja) | 2014-11-27 |
| JP2014531455A5 true JP2014531455A5 (enExample) | 2015-11-12 |
| JP6110861B2 JP6110861B2 (ja) | 2017-04-05 |
Family
ID=47018510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014532040A Active JP6110861B2 (ja) | 2011-09-23 | 2012-09-21 | ワクチン療法 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20240270829A1 (enExample) |
| EP (1) | EP2758071B1 (enExample) |
| JP (1) | JP6110861B2 (enExample) |
| KR (3) | KR102129220B1 (enExample) |
| CN (2) | CN104039346A (enExample) |
| AU (1) | AU2012312126B2 (enExample) |
| BR (1) | BR112014006871A2 (enExample) |
| CA (1) | CA2811188C (enExample) |
| DK (1) | DK2758071T3 (enExample) |
| EA (1) | EA032494B1 (enExample) |
| ES (1) | ES2712951T3 (enExample) |
| HU (1) | HUE041277T2 (enExample) |
| IL (1) | IL231564A0 (enExample) |
| MX (1) | MX350928B (enExample) |
| MY (1) | MY169574A (enExample) |
| PH (1) | PH12014500657A1 (enExample) |
| PL (1) | PL2758071T3 (enExample) |
| PT (1) | PT2758071T (enExample) |
| SG (1) | SG11201400795UA (enExample) |
| SI (1) | SI2758071T1 (enExample) |
| TR (1) | TR201901846T4 (enExample) |
| WO (1) | WO2013044147A1 (enExample) |
| ZA (1) | ZA201402071B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ630542A (en) | 2012-08-16 | 2017-06-30 | Ipierian Inc | Methods of treating a tauopathy |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| JP2017512751A (ja) | 2014-02-14 | 2017-05-25 | アイピエリアン，インコーポレイティド | タウペプチド、抗タウ抗体、およびそれらの使用方法 |
| CA3118692A1 (en) | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Cell-based gene therapy for neurodegenerative diseases |
| SG11202112329RA (en) * | 2019-05-21 | 2021-12-30 | Ac Immune Sa | Anti-abeta vaccine therapy |
| KR20250137159A (ko) | 2023-01-26 | 2025-09-17 | 에이씨 이뮨 에스에이 | 항-a베타 백신 요법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9811401A (pt) | 1997-08-28 | 2000-08-29 | Ajay North America E Som Iodo | Processos para proteger uma substância agrìcola contra pestes que são nocivas para a substância agrìcola e para a proteção de uma substãncia agrìcola, e, composição protetora para substâncias agrìcolas |
| AU2003292936A1 (en) | 2002-12-24 | 2004-07-22 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| NZ567324A (en) * | 2003-02-01 | 2009-08-28 | Wyeth Corp | Active immunization to generate antibodies to soluble A-beta |
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| JP4696079B2 (ja) * | 2003-12-17 | 2011-06-08 | ヤンセン アルツハイマー イミュノセラピー | Ａβ免疫原性ペプチド担体結合物およびそれの製造方法 |
| MX2007000998A (es) * | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| KR101152557B1 (ko) * | 2005-12-12 | 2012-09-07 | 에이씨 이뮨 에스.에이. | 치료 백신 |
| NZ581835A (en) * | 2007-06-12 | 2012-09-28 | Ac Immune Sa | Monoclonal anti beta amyloid antibody |
| HUE055739T2 (hu) * | 2009-03-18 | 2021-12-28 | Ac Immune Sa | Eljárás terápiás alkalmazásra |
-
2011
- 2011-09-23 CA CA2811188A patent/CA2811188C/en active Active
- 2011-09-23 KR KR1020197008710A patent/KR102129220B1/ko active Active
- 2011-09-23 KR KR1020137002631A patent/KR20160005380A/ko not_active Ceased
- 2011-09-23 KR KR1020167021791A patent/KR20160099732A/ko not_active Ceased
-
2012
- 2012-09-21 BR BR112014006871A patent/BR112014006871A2/pt not_active Application Discontinuation
- 2012-09-21 EP EP12772616.4A patent/EP2758071B1/en active Active
- 2012-09-21 HU HUE12772616A patent/HUE041277T2/hu unknown
- 2012-09-21 ES ES12772616T patent/ES2712951T3/es active Active
- 2012-09-21 CN CN201280057432.5A patent/CN104039346A/zh active Pending
- 2012-09-21 PT PT12772616T patent/PT2758071T/pt unknown
- 2012-09-21 EA EA201400376A patent/EA032494B1/ru not_active IP Right Cessation
- 2012-09-21 WO PCT/US2012/056728 patent/WO2013044147A1/en not_active Ceased
- 2012-09-21 CN CN201910160828.6A patent/CN109847058A/zh active Pending
- 2012-09-21 JP JP2014532040A patent/JP6110861B2/ja active Active
- 2012-09-21 PH PH1/2014/500657A patent/PH12014500657A1/en unknown
- 2012-09-21 MX MX2014003325A patent/MX350928B/es active IP Right Grant
- 2012-09-21 MY MYPI2014000851A patent/MY169574A/en unknown
- 2012-09-21 TR TR2019/01846T patent/TR201901846T4/tr unknown
- 2012-09-21 SI SI201231487T patent/SI2758071T1/sl unknown
- 2012-09-21 DK DK12772616.4T patent/DK2758071T3/en active
- 2012-09-21 PL PL12772616T patent/PL2758071T3/pl unknown
- 2012-09-21 AU AU2012312126A patent/AU2012312126B2/en active Active
- 2012-09-21 SG SG11201400795UA patent/SG11201400795UA/en unknown
-
2014
- 2014-03-18 IL IL231564A patent/IL231564A0/en active IP Right Grant
- 2014-03-20 ZA ZA2014/02071A patent/ZA201402071B/en unknown
-
2023
- 2023-12-22 US US18/395,150 patent/US20240270829A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014531455A5 (enExample) | ||
| Godyń et al. | Therapeutic strategies for Alzheimer's disease in clinical trials | |
| TWI537000B (zh) | 治療性疫苗 | |
| Bhatti et al. | Recent advances and review on treatment of stiff person syndrome in adults and pediatric patients | |
| MY183989A (en) | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease | |
| Berk et al. | Successes and failures for drugs in late-stage development for Alzheimer’s disease | |
| JP2017153480A (ja) | 治療的特性を有するβ１〜４２特異的モノクローナル抗体 | |
| JP2012522754A5 (enExample) | ||
| US20090074775A1 (en) | Use Of Anti-AB Antibody To Treat Traumatic Brain Injury | |
| RU2011144307A (ru) | Фармацевтическая композиция | |
| JP2012520852A5 (enExample) | ||
| JP2022549654A (ja) | Ｒａｎタンパク質疾患のためのワクチン治療 | |
| US20140037638A1 (en) | Compositions and methods for treating amyloid plaque associated symptoms | |
| EP1469882B1 (en) | Treatment of nervous system diseases with goat serum | |
| JP6110861B2 (ja) | ワクチン療法 | |
| JP2025506472A5 (enExample) | ||
| JP2015521636A (ja) | ｉｎ−ｖｉｖｏで神経変性疾患（特にアルツハイマー病）に活性なリポソーム | |
| Panwar et al. | Emerging Novel Therapeutic Approaches for the Treatment of Alzheimer's Disease | |
| Armentia et al. | 3 Postmarketing Study for Assessment of Tolerability of a Grass Allergen Immunotherapy Tablet (GRAZAX) in Patients With Rhinitis or Rhinoconjunctivitis | |
| Vlahovic et al. | Guillain–Barré syndrome–clinical features, outcome and prognosis | |
| Hoglund et al. | P4-386 The effect of simvastatin treatmnt the processing of the amyloid precursor protein in patients with Alzheimer's disease | |
| TH2001005860A (th) | วัคซีนทางการบำบัดชนิดต้าน a-เบตา | |
| Schoonjans et al. | Cardiovascular safety of long-term, low-dose fenfluramine use in Dravet syndrome; where are we now? | |
| Agadjanyan et al. | P4-385 Alzheimer's epitope vaccine based on the dominant B cell epitope of Aβ and padre, a foreign T cell epitope | |
| Choi et al. | P4-384 Minocycline blocks C-terminal fragments of amyloid precursor protein-induced neurotoxicity by inhibition cytochrome C release and caspase-12 activation |